MACROGENICS, INC. Deferred Tax Assets, Operating Loss Carryforwards, State and Local
MACROGENICS, INC. (MGNX) had Deferred Tax Assets, Operating Loss Carryforwards, State and Local of $33.03 million as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal · last filed 2026-03-09
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $33.03M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $31.76M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $33.35M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $44.78M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | Deferred Tax Assets, Operating Loss Carryforwards, State and Local as first filed |
|---|---|---|
| 2025-12-31 | $33.03M 10-K · filed 2026-03-09 | |
| 2024-12-31 | $31.76M 10-K · filed 2026-03-09 | |
| 2023-12-31 | $33.35M 10-K · filed 2025-03-20 | |
| 2022-12-31 | $44.78M 10-K · filed 2024-03-07 | |
| 2021-12-31 | $49.97M 10-K · filed 2023-03-15 | |
| 2020-12-31 | $37.47M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $31.11M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $22.81M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $7.55M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $6.58M 10-K · filed 2018-02-27 | |
| 2015-12-31 | $3.91M 10-K · filed 2017-02-28 | |
| 2014-12-31 | $3.72M 10-K · filed 2016-02-29 | |
| 2013-12-31 | $3.32M 10-K · filed 2015-03-03 | $3.32M 10-K · filed 2014-03-20 |
| 2012-12-31 | $3.52M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |